GlassScriptPhysician profile
Mitchell H Saferstein
NPI 1063522019
$3,901.57
in general payments reported to CMS, 2019-2025
18 companies · $847 in 2025
The $847 reported for 2025 was more than what 88% of Optometrist providers received nationally (typical 2025 total: $204).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $550 · 2020: $156 · 2021: $147 · 2022: $497 · 2023: $686 · 2024: $1,018 · 2025: $847.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,551.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,551.10 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Sun Pharmaceutical Industries INC. | $925.56 | 2019-2025 | Cequa |
| Oyster Point Pharma, INC. | $563.39 | 2022-2024 | Tyrvaya |
| Coopervision INC. | $423.82 | 2019-2025 | Misight Contact Lens, Clariti Contact Lens, Myday Contact Lens |
| Allergan, INC. | $422.61 | 2019-2022 | |
| Alcon Vision LLC | $369.83 | 2019-2024 | Precision 1 |
| Glaukos Corporation | $360.92 | 2024-2025 | Photrexa |
| Bausch & Lomb Americas INC. | $271.37 | 2022-2025 | Vyzulta, Miebo, Infuse |
| Abbvie INC. | $168.35 | 2022-2024 | |
| Tarsus Pharmaceuticals, INC. | $71.49 | 2024-2025 | Xdemvy |
| Aerie Pharmaceuticals, INC. | $67.84 | 2019-2021 | |
| Dompe US, INC. | $64.40 | 2024-2025 | Oxervate |
| Biotissue Holdings INC. | $52.69 | 2023-2024 | |
| Eyevance Pharmaceuticals LLC | $39.57 | 2021-2022 | |
| Kala Pharmaceuticals, INC. | $28.64 | 2022 | |
| Spark Therapeutics, INC. | $22.93 | 2022 |
Show all 18 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Harrow Eye, LLC | $18.99 | 2025 | Vevye |
| Novartis Pharmaceuticals Corporation | $14.97 | 2020 | |
| Shire North American Group INC | $14.20 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Mitchell Saferstein listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.